Trial | NCT02377895  Report issue

Title

Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis
A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Allergen BioCube Study Evaluating the Efficacy and Safety of Nasapaque Nasal Solution in a Population of Adult Subjects With Seasonal Allergic Rhinitis

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    iodixanol ...

  • Study Participants

    73
Single-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy and safety study using the Allergen BioCube (ABC).
Study Started
Mar 31
2015
Primary Completion
Jul 31
2015
Study Completion
Jul 31
2015
Last Update
Jan 26
2017
Estimate

Drug Nasapaque Nasal Solution

Drug Placebo Saline Nasal Solution

Nasapaque Nasal Solution Experimental

250 ul in each nostril at Day 1 and Day 8

Placebo Saline Nasal Solution Active Comparator

250 ul in each nostril at Day 1 and Day 8

Criteria 

Key Inclusion Criteria:

Must be 18 years of age and provide written informed consent and sign the HIPAA form
Must have history of allergic rhinitis
Must have positive response to Allergen BioCube

Key Exclusion Criteria:

Must not have a significant illness such as moderate to severe allergic asthmatic reactions
Must not have compromised lung function
Must not use any disallowed medications
Must not have been in an investigational study in the last 30 days
No Results Posted